Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%
August 26 2019 - 1:35PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it received a new
Abbreviated New Drug Application (ANDA) approval from the U.S. Food
and Drug Administration (FDA) for Azelastine Hydrochloride Nasal
Spray, 0.15%. The product is manufactured at Akorn’s Amityville,
New York manufacturing facility.
According to IQVIA, U.S. sales of Azelastine Hydrochloride Nasal
Spray, 0.15% were approximately $18 million for the twelve months
ended June 2019. Azelastine Hydrochloride Nasal Spray, 0.15% is
indicated for the relief of the symptoms of seasonal allergic
rhinitis in patients 6 years of age and older and perennial
allergic rhinitis in patients 6 years of age and older.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024